Adeva-Andany MM. Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage. World J Nephrol 2025; 14(4): 110990 [DOI: 10.5527/wjn.v14.i4.110990]
Corresponding Author of This Article
María M Adeva-Andany, MD, PhD, Department of Nephrology, Hospital Juan Cardona, Pardo Bazán, Ferrol 15406, Spain. madevaa@yahoo.com
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Dec 25, 2025 (publication date) through Dec 23, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Nephrology
ISSN
2220-6124
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Adeva-Andany MM. Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage. World J Nephrol 2025; 14(4): 110990 [DOI: 10.5527/wjn.v14.i4.110990]
World J Nephrol. Dec 25, 2025; 14(4): 110990 Published online Dec 25, 2025. doi: 10.5527/wjn.v14.i4.110990
Beneficial effect of sodium-glucose cotransporter 2 inhibitors on kidney function can be just a mirage
María M Adeva-Andany
María M Adeva-Andany, Department of Nephrology, Hospital Juan Cardona, Ferrol 15406, Spain
Author contributions: Adeva-Andany MM wrote the article.
Conflict-of-interest statement: There was no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: María M Adeva-Andany, MD, PhD, Department of Nephrology, Hospital Juan Cardona, Pardo Bazán, Ferrol 15406, Spain. madevaa@yahoo.com
Received: June 20, 2025 Revised: July 30, 2025 Accepted: September 17, 2025 Published online: December 25, 2025 Processing time: 186 Days and 16.2 Hours
Core Tip
Core Tip: Sodium-glucose cotransporter-2 (SGLT2) inhibitors increase long-term serum creatinine-based estimated glomerular filtration rate (GFR), but this effect may not represent a kidney protective effect. Subjects undergoing osmotic diuresis exhibit glomerular hyperfiltration. In patients receiving SGLT2 inhibitors, the elevated estimated GFR may reflect an adaptive response to osmotic diuresis rather than an improvement of kidney function. In addition, loss of skeletal muscle mass has been consistently associated with use of SGLT2 inhibitors. In patients with reduced muscle mass, serum creatinine-based estimation of GFR produces a deceptive increase of estimated GFR. In patients receiving SGLT2 inhibitors, increased estimated GFR may represent an overestimation of the factual kidney function rather than an actual improvement.
